These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8607524)

  • 41. Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation.
    Wang Y; Yamaguchi Y; Watanabe H; Ohtsubo K; Wakabayashi T; Sawabu N
    J Gastroenterol; 2002; 37(10):831-9. PubMed ID: 12424567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical significance of YH-206 assay analysis as a tumor marker].
    Yachi A; Hinoda Y; Imai K; Endo T
    Nihon Rinsho; 1990 Feb; 48 Suppl():1068-70. PubMed ID: 2192107
    [No Abstract]   [Full Text] [Related]  

  • 43. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
    Shimada H; Ochiai T; Nomura F;
    Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
    Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
    Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Differential diagnosis].
    Koshita S; Kobayashi G; Noda Y; Ito K; Kanno Y
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():119-24. PubMed ID: 25856998
    [No Abstract]   [Full Text] [Related]  

  • 46. Serum p53 antibodies as an early detection marker in colorectal cancer.
    Takeda A; Shimadai H; Iseki H; Saeki T; Koyama I
    Hepatogastroenterology; 2007 Sep; 54(78):2 pages preceeding table of content. PubMed ID: 18019675
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
    Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
    Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
    Huang C; Bei L; Liu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer.
    Agaylan A; Binder D; Sauer M; Neuweiler H; Meyer O; Kiesewetter H; Salama A
    Cancer; 2007 Dec; 110(11):2502-6. PubMed ID: 17932907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
    Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
    Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
    Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
    Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
    Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses.
    Itoi T; Takei K; Sofuni A; Itokawa F; Tsuchiya T; Kurihara T; Nakamura K; Moriyasu F; Tsuchida A; Kasuya K
    Oncol Rep; 2005 Feb; 13(2):229-34. PubMed ID: 15643503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid and sensitive immunomagnetic-electrochemiluminescent detection of p53 antibodies in human serum.
    Yan G; Xing D; Tan S; Chen Q
    J Immunol Methods; 2004 May; 288(1-2):47-54. PubMed ID: 15183084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analog diagnosis in a digital world: the quest to improve endoscopic tissue acquisition and diagnostic sensitivity in malignant biliary stricture.
    Kozarek RA
    Clin Gastroenterol Hepatol; 2004 Mar; 2(3):207-8. PubMed ID: 15017603
    [No Abstract]   [Full Text] [Related]  

  • 56. [Urinary free L-fucose (UFC) and urinary sulfated bile acids (U-SBA)].
    Mashige F
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():774-8. PubMed ID: 16149638
    [No Abstract]   [Full Text] [Related]  

  • 57. [X-ray and radioisotopic investigational methods in tumors of the duodenopancreaticobiliary area].
    Gabuniia RI; Petsko AR; Vinogradov VA; Kuvshinov IuP
    Med Radiol (Mosk); 1980 Sep; 25(9):48-53. PubMed ID: 7421440
    [No Abstract]   [Full Text] [Related]  

  • 58. Pancreaticobiliary malignancies: past, present, and future.
    Herman JM
    Semin Radiat Oncol; 2014 Apr; 24(2):61-6. PubMed ID: 24635862
    [No Abstract]   [Full Text] [Related]  

  • 59. [CA 19-9, a new tumor marker].
    Akai S
    Rinsho Byori; 1983 Dec; 31(12):1300-2. PubMed ID: 6587136
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunocytochemical assessment of p53 protein to detect malignancy in increased cell-yield brush cytology from the biliopancreatic tree.
    Villanacci V; Cestari R; Giulini S; Cengia P; Missale G; Berenzi A; Rossi E; Bonardi M; Baiocchi L; Bassotti G
    Dig Dis Sci; 2009 Apr; 54(4):789-92. PubMed ID: 18688713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.